Forest Laboratories

Forest Laboratories is a pharmaceutical company headquartered in New York City, USA. Its revenues for the year ended 31 March 2007 were US$3.4 billion. The company's research & development spending has grown rapidly in recent years, and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending [cite web |url=http://ir.frx.com/phoenix.zhtml?c=83198&p=irol-IRHome |title=Forest Laboratories financial statements |accessdate=2007-11-15] [cite web |url=http://www.innovation.gov.uk/rd_scoreboard/?p=68 |title=The 1250 Largest Companies Worldwide in R&D Spending|accessdate=2007-11-15] . Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.

One of Forest Laboratories' best sellers is the antidepressant, Lexapro, which was developed in cooperation with Danish company, Lundbeck. Forest also has a drug for the treatment of Alzheimer's disease called Namenda. Namenda has been licensed in Europe for approximately the last 30 years, but has only been licensed in the USA in the last two years. Both Lexapro and Namenda are produced in bulk at the Forest plant in Dublin, Ireland, with secondary processing, such as bottling and blister-packing, being carried out in the USA at plants in New York and St. Louis. Forest's also produces Campral for the maintenance of abstinence from alcohol in patients with alcohol dependence. Other products include Tiazac, Armour Thyroid, Levothroid, Thyrolar, Cervidil, Infasurf, Combunox, and Aerobid.

Forest Laboratories is listed on the New York Stock Exchange under FRX.

It should not be confused with the Forest Products Laboratory.

Footnotes

External links

* [http://www.frx.com Forest Laboratories]
* [http://www.lexapro.com Lexapro]
* [http://www.namenda.com Namenda]